Acuta Capital Partners, LLC Aligos Therapeutics, Inc. Transaction History

Acuta Capital Partners, LLC

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2021 Nov 15, 2021	SELL	$14.57 - $17.72 $3.12 Million - $3.8 Million	-214,254 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$20.3 - $33.6 $4.35 Million - $7.2 Million	214,254 New	214,254 $4.37 Million

240K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $751M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.